Although the first approved PARPi (olaparib) initially targeted patients with ovarian cancer that carried germline mutations in the BRCA1 or BRCA2 genes, a later study demonstrated responses with olaparib in 41% and 24% of germline BRCA mutation carriers and non-carriers, respectively [12]. This evidence concerns the gene BRCA1 and ovarian cancer.